Product Description
For Diabetes Mellitus (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01380873)
Mechanisms of Action: GH Inhibitor, AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: HK inno.N
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|General Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01380873 |
CJ_VCM_103 | P1 |
Completed |
General Diabetes|Healthy Volunteers |
2010-02-01 |
2020-07-16 |
Primary Endpoints |
|
NCT01370681 |
CJ_VCM_102 | P1 |
Completed |
Healthy Volunteers|General Diabetes |
2009-11-01 |
2020-07-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|